Summary
• Intensity Therapeutics, Inc. (INTS) is up 6% in pre-market trading, at $0.4196.
• The company reported a cash position of $7.1 million and plans to resume patient enrollment in its IT-01 study in Q1 2026.
• Analysts maintain a “Buy” rating, highlighting a 43.4% monthly performance increase despite a year-to-date decline of 74.1%.
Intensity Therapeutics, Inc. (INTS) is seeing a solid pre-market performance, currently trading at $0.4196, up 6% from its last close of $0.3955. This uptick occurs amid routine trading conditions and without a defined catalyst.
Corporate Update Sparks Interest
On November 6, 2025, Intensity Therapeutics reported its third-quarter financial results, including a corporate update detailing future plans for its clinical studies. The company expects to file a protocol amendment for the INVINCIBLE-4 study to revise the dosing regimen for the INT230-6 treatment cohort. Additionally, patient enrollment in the IT-01 study is set to resume in the first quarter of 2026.
The update highlighted a cash position of $7.1 million as of September 30, 2025, with an additional $6.1 million raised in the fourth quarter of the same year. This funding effectively extends the company’s cash runway until the end of Q1 2027.
Market and Technical Picture
INTS has experienced significant volatility, showcasing a monthly performance increase of 43.4%, despite a year-to-date decline of 74.1%. Its current average volume over the past 10 days stands at approximately 1.8 million shares, while the three-month average volume is over 28 million.
Technical indicators show the stock’s RSI at 48.5, suggesting it is nearing neutral territory after a considerable downside trend over the past year. The stock’s performance has been mixed overall, with the 20-day simple moving average (SMA) at -21.7% and the 50-day SMA at +10.0%.
Analyst Sentiment
Analysts maintain a “Buy” rating on the stock, reflecting optimism regarding its long-term prospects. Intensity Therapeutics has also shown resilience, overcoming a 85.8% decline over the past year as it continues to advance its clinical trial agenda.
As shares of Intensity Therapeutics reflect this latest corporate update in trading, investors are likely to keep a close eye on the company’s upcoming initiatives and overall market performance as it approaches key enrollment phases for its treatments.